Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.
Level 4 - case-series / case-control
Case series of two patients without a control group.
PubMed 39981248 · doi:10.3389/fimmu.2025.1535782
What was done
Two patients with multiple sclerosis (MS) underwent an experimental ibogaine treatment regimen. Investigators evaluated clinical responses and neuroimaging changes, including lesion size, Apparent Diffusion Coefficient (ADC) values, and cortical/subcortical structural alterations.
What was found
The abstract reports no exact quantitative measurements. Qualitatively, Patient A showed substantial lesion shrinkage and decreased ADC values. Both patients exhibited structural cortical and subcortical changes, primarily in brain regions associated with emotional and pain processing.
Why it matters
These observations provide preliminary, hypothesis-generating anecdotal evidence regarding potential structural neural alterations or remyelination following ibogaine administration in MS.
Limits
The study is limited to two patients with no control group or blinding, making causal inference impossible. The abstract does not provide exact quantitative metrics, treatment dosing, follow-up duration, or safety and toxicity data.
Cited by
- supports A case report of two multiple sclerosis patients treated with ibogaine documented a 70% reduction in brain white matter lesions.